Semaglutide Weight Management and Cardiovascular Risk Reduction
OASIS 1 with oral semaglutide 50 mg in people with overweight
or obesity has been successfully completed
OASIS 1 enrolled 667 patients with overweight or obesity
Oral Semaglutide 50 mg*
R
Placebo*
1:1
68 Weeks
Lifestyle intervention
7 weeks
follow-up
Objective:
•
To compare the safety and efficacy of 50 mg oral semaglutide with
placebo in people with overweight or obesity without T2D
Co-primary endpoints:
•
Percentage change in body weight from baseline to week 68
Achievement of ≥5% weight loss from baseline at week 68
Confirmatory secondary endpoints:
•
Achievement of ≥10%, ≥15% and ≥20% weight loss from baseline
at week 68
Inclusion criteria:
•
⚫ BMI: ≥27 kg/m² with ≥ 1 weight-related comorbidity, or
•
BMI: ≥30 kg/m²
•
.
Weight-related comorbidities are hypertension, dyslipidaemia,
obstructive sleep apnoea and CVD
• ≥1 self-reported dietary weight loss effort
*As an adjunct to a reduced-calorie diet and increased physical activity in adults with obesity or with overweight and weight-related comorbidities (Weight-related comorbidities are hypertension, dyslipidaemia, obstructive sleep apnoea and CVD)
T2D: Type 2 diabetes; R: Randomisation; BMI: body mass indexView entire presentation